Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immunotherapy alone or in combination with chemotherapy.
Giuseppe Luigi BannaOrnella CantaleAlex FriedlaenderHarliana YusofShyamika AcharigeAlfredo AddeoPublished in: Cancer investigation (2021)
The addition of ChT to immunotherapy could be associated with increased risk of mortality and higher SARS-CoV-2-related mortality rate.